Published Manuscripts (2020)

Bain SC, Bekker Hansen B, Hunt B, Chubb B, Valentine WJ. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. Journal of Medical Economics 2020; 23(1): 98-105.

Gorgojo-Martínez JJ, Malkin SJP, Martín V, Hallén N, Hunt B. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. Journal of Medical Economics 2020; 23(2): 193-202.

Bain SC, Hansen BB, Malkin SJP, Nuhoho S, Valentine WJ, Chubb B, Hunt B, Capehorn M. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme. Diabetes Therapy 2020; 11(1): 259-277.

Vidal J, Malkin SJP, Hunt B, Martín V, Hallén N, Javier Ortega F. The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain. Diabetes Therapy 2020; 11(2); 509-521.

Cannon AJ, Bargiota A, Billings L, Hunt B, Leiter LA, Malkin S, Mocarski M, Ranthe MF, Schiffman A, Doshi A. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets. Journal of Managed Care & Specialty Pharmacy 2020; 26(2): 143-153.

Ali SN, Dang-Tan T, Valentine WJ, Hansen BB. Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States. Advances in Therapy 2020; 37(2): 869-882.

Smith-Palmer J, Cerri K, Sbarigia U, Chan EKH, Pollock RF, Valentine WJ, Bonroy K. Impact of Stigma on People Living with Chronic Hepatitis B. Patient Related Outcome Measures 2020; 11: 95-107.

Johansen P, Chubb B, Hunt B, Malkin SJP, Sandberg A, Capehorn M. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. Advances in Therapy 2020; 37(5): 2427-2441.

Hansen BB, Nuhoho S, Ali SN, Dang-Tan T, Valentine WJ, Malkin SJP, Hunt B. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Journal of Medical Economics 2020; 23(6): 650-658.

Roze S, Isitt J, Smith-Palmer J, Javanbakht M, Lynch P. Long-term Cost-Effectiveness of Dexcom G6 Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K. Diabetes Care 2020; 43(10):2411-2417. 

Jendle J, Ericsson Å, Ekman B, Sjöberg S, Gundgaard J, da Rocha Fernandes J, Mårdby AC, Hunt B, Malkin SJP, Thunander M. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective. Journal of Medical Economics 2020; 23(11): 1311-1320.

Martín V, Vidal J, Malkin SJP, Hallén N, Hunt B. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. Advances in Therapy 2020;37(10): 4427-4445.

Igarashi A, Hunt B, Wilkinson L, Langer J, Pollock RF. Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis. Advances in Therapy 2020; 37(10): 4446-4457.

Pöhlmann J, Norrbacka K, Boye KS, Valentine WJ, Sapin H. Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy. The European Journal of Health Economics 2020; 21(8): 1179-1196.

Leeuwenkamp O, Smith-Palmer J, Ortiz R, Werner A, Valentine W, Blachier M, Walter T. Cost-effectiveness of Lutetium [ 177 Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France. Journal of Medical Economics 2020;23(12):1534-1541.

Close phone HUD
+41 61 271 6214
Dial with SkypeOutDial with SkypeOut
Close phone HUD
+41 79 340 4644
Dial with SkypeOutDial with SkypeOut